Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Vet Intern Med ; 32(1): 370-376, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29080252

RESUMO

BACKGROUND: Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion/diuresis volume in clinical trials in humans. HYPOTHESIS/OBJECTIVES: We hypothesized that Tavocept would decrease diuresis volume and time and facilitate safe administration of a cisplatin/piroxicam protocol to dogs with bladder cancer. Secondary objectives were to compare response rate and survival times to an historical comparator group treated without Tavocept. ANIMALS: Fourteen client-owned dogs were prospectively enrolled. METHODS: Tumor volume was measured by computed tomography at days 0, 42, and 84. Dogs received combination Tavocept/cisplatin with a shortened diuresis protocol. A total of 4 doses was planned, with concurrent administration of piroxicam. Serial biochemical analyses were evaluated for azotemia. RESULTS: A 90-minute infusion/diuresis time was used for all dogs. Three dogs (21%) had concurrent increases in serum creatinine (>2.0 mg/dL) and BUN (>42 mg/dL) concentrations; 2 of these dogs were isosthenuric. This frequency of nephrotoxicity is significantly less (P = 0.0406) than that of an historical control group treated without Tavocept. Overall response rate was 27%. Median survival time was comparable to historical controls (253 vs. 246 days). CONCLUSIONS AND CLINICAL IMPORTANCE: Tavocept decreased the required diuresis time with cisplatin from > 6 hours to 90 minutes, while also decreasing occurrence of azotemia. Survival time was comparable, but the response rate was inferior to an historical comparator group. Further evaluation in other tumors susceptible to platinum agents is warranted.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma de Células de Transição/veterinária , Cisplatino/uso terapêutico , Diurese/efeitos dos fármacos , Doenças do Cão/tratamento farmacológico , Mesna/análogos & derivados , Neoplasias da Bexiga Urinária/veterinária , Animais , Antineoplásicos/efeitos adversos , Nitrogênio da Ureia Sanguínea , Carcinoma de Células de Transição/tratamento farmacológico , Cisplatino/efeitos adversos , Creatinina/sangue , Cães , Quimioterapia Combinada , Mesna/uso terapêutico , Piroxicam/uso terapêutico , Estudos Prospectivos , Insuficiência Renal/induzido quimicamente , Resultado do Tratamento , Neoplasias da Bexiga Urinária/tratamento farmacológico
3.
Appl Ergon ; 9(3): 151-4, 1978 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15677265

RESUMO

Little effort has been put into studying the noise climate inside passenger vehicles. This paper shows that noise levels in motor cars and heavy goods vehicles are unacceptable to the passenger at typical cruising speeds. It is suggested that one factor responsible for this state of affairs is the lack of criteria for acceptable noise levels. Research into the subjective response to noise in motor vehicles, both on the road and in the laboratory, is described. The importance of very low frequencies is shown in determining levels of comfort, as well as the difficulties in accurately reproducing in-vehicle noise in the laboratory. A tentative criterion is given for acceptable noise levels in passenger vehicles and work is described which, it is hoped, will lead to a more precise measure of subjective rating.

6.
Acta Otolaryngol ; 64(3): 205-12, 1967 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-6078467
8.
J Acoust Soc Am ; 40(4): 914, 1966 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-5923890

Assuntos
Audiometria , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...